Nuvation Bio, Inc. Class A NUVB

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.5% and the State

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for IBTROZI® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ non small cell lung cancer regardless of prior chemotherapy exposure. IBTROZI efficacy was reported as consistent across different ROS1 fusion partners in patients with advanced ROS1+ non small cell lung cancer. These IBTROZI subgroup findings matter, but investors may wish to weigh them alongside...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new subgroup analyses from the pivotal TRUST-I and TRUST-II studies evaluating IBTROZI® (taletrectinib) in both TKI- naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The data, presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea, demonstrated that IBTROZ

Cramer flagged the company as too risky for most people, even as the stock climbs on real medical news.

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at the following conferences:

The bank just put a big number on a small biotech company, and the target rests on a newly launched drug.

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant selective inhibitor of mutant IDH1.

Moby summary of Nuvation Bio Inc.'s Q2 2026 earnings call

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?